Federal Marijuana Rescheduling: What the AG’s Schedule III Order Means for Cannabis Businesses in 2026

Quick Summary

  • Marijuana rescheduling 2026
  • FDA approved marijuana based drugs moved from Schedule I to Schedule III
  • State licensed medical marijuana moved from Schedule I to Schedule III
  • IRS Section 280E tax burden lifted for medical operators
  • Recreational and unlicensed cannabis remains Schedule I (for now)
  • DEA hearing scheduled for June 29, 2026
  • Full federal rescheduling possible by late 2026

What Happened on April 23, 2026

In one of the most consequential federal cannabis policy decisions in decades, the Acting Attorney General signed an order immediately rescheduling FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).

At the same time, the Department of Justice announced an expedited administrative hearing beginning June 29, 2026, to evaluate broader marijuana rescheduling.

How We Got Here: A Brief Timeline

Biden Administration Review (2022–2024)

In October 2022, President Biden directed federal agencies to reassess marijuana’s Schedule I classification. By August 2023, the Department of Health and Human Services concluded marijuana has accepted medical use and recommended Schedule III classification.

DOJ Proposed Rule & Delays

In May 2024, the DOJ issued a proposed rule that generated nearly 43,000 public comments. However, the administrative process stalled due to litigation and agency conflicts.

Executive Order & Final Action

In December 2025, President Trump issued an Executive Order that directed expedited action for rescheduling. Pursuant to an Order from the Department of Justice signed by Acting Attorney General Todd Blanche rescheduling will occur in phases.

What the Order Does

 Immediate Rescheduling

The order immediately moves the following into Schedule III:

Expedited Hearing Process

A new DEA administrative hearing will determine whether all marijuana, including recreational use, should be moved to Schedule III.

Section 280E Tax Relief: The Biggest Impact

The most immediate impact is relief from IRS Section 280E.

Previously, cannabis businesses could not deduct standard business expenses due to Schedule I classification. This led to effective tax rates as high as 70%.

Now, state-licensed medical marijuana operators can:

  • Deduct payroll, rent, marketing, and operating costs
  • Significantly reduce federal tax liability
  • Increase profitability and reinvestment capacity
  • Some estimate that this could lead to an over 2 billion dollar industry wide cash flow increase.
Note: Retroactive tax relief for state licensed medical marijuana companies is possible but not guaranteed.

Expanded Research Access

Rescheduling to Schedule III classification also reduces research barriers by:

  • Simplifying DEA registration requirements
  • Expanding access to standardized cannabis for studies
  • Increasing eligibility for federal funding

This could accelerate pharmaceutical and medical cannabis development.

What the Order Does NOT Do

  • Does NOT federally legalize marijuana
  • Does NOT include recreational cannabis (application remains unclear for dual-licensed businesses that hold medical and recreational licenses)
  • Does NOT fix cannabis banking limitations
  • Does NOT override state cannabis laws
  • Does NOT create new FDA-approved products
  • Does NOT guarantee retroactive 280E refunds or relief

Impact on Cannabis Businesses

Medical Marijuana Operators

State Licensed Medical operators benefit immediately:

  • Full 280E tax relief
  • Improved margins and cash flow, but there could be new compliance requirements forthcoming

Recreational Marijuana Operators

The impact on recreational only businesses and businesses holding dual medical and adult use licenses remains somewhat unclear. Taking a conservative approach, today’s executive order would not impact recreational licensed cannabis businesses currently.

Dual licensed operators may qualify for partial tax relief, depending on a various factors.  Further action on rescheduling and impacts for recreational licensees will likely be determined through the hearing scheduled for June.

The June 29, 2026 Hearing: What to Expect

What the Hearing Covers

The hearing evaluates whether all marijuana should be rescheduled to Schedule III.

How the Process Works

  • Conducted by a DEA Administrative Law Judge
  • Includes expert testimony and legal arguments
  • Must meet Administrative Procedure Act standards

Expected Timeline

  • Hearing concludes: July 2026
  • Final Rule possible: Late 2026
  • Implementation delay: 30–90 days after publication

Litigation Risk

Legal challenges may delay implementation through:

  • Injunctions
  • Appeals
  • Administrative disputes

Bottom Line for Cannabis Operators

This is a significant shift in federal cannabis policy, but it is not full legalization.

State licensed medical marijuana operators benefit immediately. Recreational businesses must wait for clarification and action, but should continue operating in compliance with state laws

Action steps:

  • Consult a cannabis attorney
  • Consult cannabis tax professionals
  • Reevaluate financial projections
  • Review licensing structure
  • Monitor federal rule making updates

Disclaimer

This content is for informational purposes only and does not constitute legal or tax advice. Consult a licensed professional for guidance specific to your business.